ArticlePediatric nephrology (Berlin, Germany)2011
Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
Article in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.PloS one · 2015Trial
- Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression: The CKD in Children Study.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Activin A: a marker of mineral bone disorder in children with chronic kidney disease?Pediatric nephrology (Berlin, Germany) · 2024Article
- Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to end‑stage renal disease.Experimental and therapeutic medicine · 2023Article
- Muscle-bone axis in children with chronic kidney disease: current knowledge and future perspectives.Pediatric nephrology (Berlin, Germany) · 2021Review
- The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives.Journal of nephrology · 2016Review
- Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Lipids in health and disease · 2016Article
- Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature.Current osteoporosis reports · 2015Review
- Disordered FGF23 and mineral metabolism in children with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2014Observational
- Therapy for patients with CKD and low bone mineral density.Nature reviews. Nephrology · 2013Review
- Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.Kidney international · 2013Article
- Bone disease in pediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2013Review
- Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.BMC nephrology · 2013Article
- Mineral and bone disorders in children with chronic kidney disease.Nature reviews. Nephrology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoprotegerin (OPG), receptor activator of the nuclear factor κB ligand (RANKL) and fibroblast growth factor-23 (FGF-23) play a central role in renal osteodystrophy. We evaluated OPG/RANKL and FGF-23 levels in 51 children with chronic kidney disease (CKD) [n = 26 stage 3 or 4 (CKD3-4) and n = 25 stage 5 (CKD5)] and 61 controls. Any possible association with intact parathyroid hormone (iPTH) and bone turnover markers was also investigated. The OPG levels were lower in the CKD3-4 group (p < 0.001) and higher in the CKD5 group (p < 0.01) than in the controls, while RANKL levels did not differ. The FGF-23 levels were higher in both patient groups (p < 0.0001), while the levels of phosphate and iPTH were higher only in the CKD5 group (p < 0.0001). There were independent positive correlations between OPG and RANKL (β = 0.297, p < 0.01) and FGF-23 (β = 0.352, p < 0.05) and a negative correlation with the bone resorption marker TRAP5b (β = -0.519, p < 0.001). OPG was positively correlated with iPTH (R = 0.391, p < 0.01). An independent positive correlation between FGF-23 and phosphate (β = 0.368, p < 0.05) or iPTH (β = 0.812, p < 0.0001) was noted. In conclusion, we found that higher OPG levels in patients with CKD stage 5 correlated with the levels of RANKL, FGF-23, iPTH, and TRAP5b. These findings may reflect a compensatory mechanism to the negative balance of bone turnover. High FGF-23 levels in early CKD stages may indicate the need for intervention to manage serum phosphate (Pi) levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.